259 related articles for article (PubMed ID: 27880934)
21. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.
Vedeld HM; Merok M; Jeanmougin M; Danielsen SA; Honne H; Presthus GK; Svindland A; Sjo OH; Hektoen M; Eknaes M; Nesbakken A; Lothe RA; Lind GE
Int J Cancer; 2017 Sep; 141(5):967-976. PubMed ID: 28542846
[TBL] [Abstract][Full Text] [Related]
22. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
[TBL] [Abstract][Full Text] [Related]
23. The role of the CpG island methylator phenotype on survival outcome in colon cancer.
Kang KJ; Min BH; Ryu KJ; Kim KM; Chang DK; Kim JJ; Rhee JC; Kim YH
Gut Liver; 2015 Mar; 9(2):202-7. PubMed ID: 25167802
[TBL] [Abstract][Full Text] [Related]
24. CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China.
Li X; Hu F; Wang Y; Yao X; Zhang Z; Wang F; Sun G; Cui BB; Dong X; Zhao Y
Biomed Res Int; 2014; 2014():236361. PubMed ID: 25243122
[TBL] [Abstract][Full Text] [Related]
25. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
[TBL] [Abstract][Full Text] [Related]
26. CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas.
Sun L; Guzzetta AA; Fu T; Chen J; Jeschke J; Kwak R; Vatapalli R; Baylin SB; Iacobuzio-Donahue CA; Wolfgang CL; Ahuja N
Epigenetics; 2014 May; 9(5):738-46. PubMed ID: 24518818
[TBL] [Abstract][Full Text] [Related]
27. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
28. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
Min BH; Bae JM; Lee EJ; Yu HS; Kim YH; Chang DK; Kim HC; Park CK; Lee SH; Kim KM; Kang GH
BMC Cancer; 2011 Aug; 11():344. PubMed ID: 21827707
[TBL] [Abstract][Full Text] [Related]
29. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
Jia M; Jansen L; Walter V; Tagscherer K; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
Br J Cancer; 2016 Nov; 115(11):1359-1366. PubMed ID: 27811854
[TBL] [Abstract][Full Text] [Related]
30. Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort.
Chen KH; Lin LI; Yuan CT; Tseng LH; Chao YL; Liang YH; Liang JT; Lin BR; Cheng AL; Yeh KH
Br J Cancer; 2021 Jul; 125(1):48-54. PubMed ID: 33846524
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma.
An C; Choi IS; Yao JC; Worah S; Xie K; Mansfield PF; Ajani JA; Rashid A; Hamilton SR; Wu TT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):656-63. PubMed ID: 15701853
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
33. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
34. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
[TBL] [Abstract][Full Text] [Related]
35. Meta-Analysis of the Prognostic and Predictive Role of the CpG Island Methylator Phenotype in Colorectal Cancer.
Wang J; Deng Z; Lang X; Jiang J; Xie K; Lu S; Hu Q; Huo Y; Xiong X; Zhu N; Zhang W
Dis Markers; 2022; 2022():4254862. PubMed ID: 36157209
[TBL] [Abstract][Full Text] [Related]
36. Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.
Koh YW; Chun SM; Park YS; Song JS; Lee GK; Khang SK; Jang SJ
Tumour Biol; 2016 Aug; 37(8):10675-84. PubMed ID: 26867769
[TBL] [Abstract][Full Text] [Related]
37. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.
Zhang X; Shimodaira H; Soeda H; Komine K; Takahashi H; Ouchi K; Inoue M; Takahashi M; Takahashi S; Ishioka C
Int J Clin Oncol; 2016 Dec; 21(6):1091-1101. PubMed ID: 27435270
[TBL] [Abstract][Full Text] [Related]
38. Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.
Bae JM; Kim JH; Kwak Y; Lee DW; Cha Y; Wen X; Lee TH; Cho NY; Jeong SY; Park KJ; Han SW; Lee HS; Kim TY; Kang GH
Br J Cancer; 2017 Apr; 116(8):1012-1020. PubMed ID: 28278514
[TBL] [Abstract][Full Text] [Related]
39. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427
[TBL] [Abstract][Full Text] [Related]
40. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
